Aim We previously reported the outcome of chromic phosphate‐32(32P) colloid synoviorthesis in 53 haemophilic patients with an average follow‐up of 31 months. The purpose of the present study was the long‐term follow‐up of the same cohort on both clinical and radiographic features. Materials Nine patients failed to attend the recall appointment. The mean follow‐up for the remaining 44 patients (52 procedures) was 15 years (range, 14.6‐15.5). The mean age at the time of reassessment was 31 years (range, 18‐43). Results The haemarthrosis frequency was not statistically significant at the latest follow‐up years compared with 31 months (0.8 vs 0.4 per week, P = .3). There was no significant change in the clinical severity of haemophilic arthropathy (P = .5). Most of the treated joints still are in stage III of Fernandez‐Palazzi and Caviglia classification. There was a trend towards the radiologic deterioration of arthritis with nearly 50% of patients at Arnold‐Hilgartner Stage V. 13% of patients underwent a total knee arthroplasty (TKA). The age at which the initial radiosynovectomy was performed was significantly higher in patients who had a TKA than those who had not (22 vs 15 years, P < .002). Conclusion The bleeding control effect of 32P on the target joint remains over time; however, it did not appear to halt the progression of radiographic changes in haemophiliacs. It could delay the need for TKA if it performs at the right time.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.